Novocure Ltd
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Frank Leonard
- Full Time Employees
- 1,605
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Neuhofstrasse 21 Baar Switzerland 6340
- IPO Date
- Oct 2, 2015
- CIK
- 0001645113
- Website
- novocure.com
- Similar Companies
- Business
- NovoCure Limited (Nasdaq: NVCR) is a global oncology company that develops, manufactures and commercializes Tumor Treating Fields (TTFields) therapy, a non-invasive anti-mitotic treatment delivered via wearable devices that disrupt cancer cell division in solid tumors. Its main commercialized products include Optune Gio, approved for adult patients with glioblastoma (GBM), and Optune Lua, approved for malignant pleural mesothelioma (MPM); in 2024, the U.S. FDA expanded approvals to include TTFields therapy concurrently with PD-1/PD-L1 inhibitors or docetaxel for metastatic non-small cell lung cancer (mNSCLC) following platinum-based therapy, and approved new Head Flexible Electrode (HFE) transducer arrays to enhance patient comfort in GBM treatment. The company conducts Phase 3 clinical trials such as PANOVA-3 (pancreatic cancer), LUNAR-2 and METIS (lung and brain metastases), and TRIDENT (ovarian cancer), targeting additional aggressive cancers. Founded in 2000 and headquartered in Baar, Switzerland, with U.S. operations in Portsmouth, New Hampshire, and R&D in Haifa, Israel, NovoCure operates in the United States, Germany, France, Japan, Greater China and other international markets. Recent developments include the January 2025 inauguration of new global headquarters in the Canton of Zug, Switzerland, to support expansion; a multi-tranche $400 million non-dilutive debt financing with Pharmakon Advisors, with $100 million drawn at closing and more available through 2025; and positive topline results from the Phase 3 PANOVA-3 trial demonstrating statistically significant overall survival improvement in unresectable pancreatic cancer.
NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
NovoCure: 'Buy' TRIDENT Setback And TTFields FDA Decision Q4 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
NovoCure's Cancer Treatment Device Option Pax Gets European Approval
Novocure to Report Second Quarter 2026 Financial Results
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
Novocure's Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026?
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)
Novocure's cancer treatment fails to meet late-stage trial goal
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
CEO Sells 34K Shares of Biotech Stock, Valued at $615,000, According to Latest SEC Filing